Standard Chemical & Pharmaceutical Co. Ltd. (1720.TW)
- Previous Close
58.10 - Open
58.00 - Bid 57.70 x --
- Ask 57.80 x --
- Day's Range
57.70 - 58.10 - 52 Week Range
51.20 - 79.40 - Volume
117,705 - Avg. Volume
195,469 - Market Cap (intraday)
10.311B - Beta (5Y Monthly) 0.00
- PE Ratio (TTM)
12.54 - EPS (TTM)
4.60 - Earnings Date Aug 6, 2025 - Aug 13, 2025
- Forward Dividend & Yield 2.70 (4.68%)
- Ex-Dividend Date Aug 1, 2024
- 1y Target Est
73.00
Standard Chemical & Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products, supplements, and APIs in Taiwan and internationally. The company offers various pharmaceutical products for metabolic, respiratory, musculoskeletal, digestive, circulatory system, topical dermatological, cardiovascular system, anti-infectives, urogenital system and sex hormones, and others. It engages in processing, manufacturing, and selling of food; and offers western medicine, nourishment, and function food, biochemical nutrition, and preventive medicines. In addition, the company offers multi- function printers and information software. Standard Chemical & Pharmaceutical Co. Ltd. was incorporated in 1967 and is headquartered in Tainan City, Taiwan.
www.standard.com.tw--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 1720.TW
View MorePerformance Overview: 1720.TW
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1720.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1720.TW
View MoreValuation Measures
Market Cap
10.31B
Enterprise Value
9.21B
Trailing P/E
12.54
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.51
Price/Book (mrq)
1.84
Enterprise Value/Revenue
1.35
Enterprise Value/EBITDA
4.66
Financial Highlights
Profitability and Income Statement
Profit Margin
12.07%
Return on Assets (ttm)
7.46%
Return on Equity (ttm)
14.82%
Revenue (ttm)
6.82B
Net Income Avi to Common (ttm)
822.47M
Diluted EPS (ttm)
4.60
Balance Sheet and Cash Flow
Total Cash (mrq)
1.95B
Total Debt/Equity (mrq)
7.39%
Levered Free Cash Flow (ttm)
796.52M